Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Virology

• Publication date

  2014-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.virol.2014.08.008PMID 25213406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MVA Vectors Expressing Conserved Influenza Proteins Protect Mice against Lethal Challenge with H5N1, H9N2 and H7N1 Viruses

  2014cited by this paper
• DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin.

  2014cited by this paper
• Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1

  2013cited by this paper
• Single-Dose Vaccination of a Recombinant Parainfluenza Virus 5 Expressing NP from H5N1 Virus Provides Broad Immunity against Influenza A Viruses

  2013cited by this paper
• New Orf Virus (Parapoxvirus) Recombinant Expressing H5 Hemagglutinin Protects Mice against H5N1 and H1N1 Influenza A Virus

  2013cited by this paper
• Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection

  2013cited by this paper
• Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

  2013cited by this paper
• Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.

  2013cited by this paper
• Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus

  2013cited by this paper
• Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine

  2013cited by this paper
• Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T‐cell responses

  2013cited by this paper
• Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.

  2013cited by this paper
• Influenza Nucleoprotein Delivered with Aluminium Salts Protects Mice from an Influenza A Virus That Expresses an Altered Nucleoprotein Sequence

  2013cited by this paper
• Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

  2013cited by this paper
• Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

  2012cited by this paper
• Immunity to the Conserved Influenza Nucleoprotein Reduces Susceptibility to Secondary Bacterial Infections

  2012cited by this paper
• Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].

  2012cited by this paper
• Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans

  2012cited by this paper
• Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.

  2012cited by this paper
• Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice

  2012cited by this paper
• Robust Immunity and Heterologous Protection against Influenza in Mice Elicited by a Novel Recombinant NP-M2e Fusion Protein Expressed in E. coli

  2012cited by this paper
• A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years

  2012cited by this paper
• Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein

  2012cited by this paper
• Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease.

  2011cited by this paper
• Broad Humoral and Cellular Immunity Elicited by a Bivalent DNA Vaccine Encoding HA and NP Genes from an H5N1 Virus

  2011cited by this paper
• Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

  2011cited by this paper
• Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

  2011cited by this paper
• Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance

  2011cited by this paper
• Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine.

  2011cited by this paper
• A DNA Vaccine-Encoded Nucleoprotein of Influenza Virus Fails To Induce Cellular Immune Responses in a Diabetic Mouse Model

  2010cited by this paper
• Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein

  2010influential reference
• Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses

  2010cited by this paper
• New horizons in adjuvants for vaccine development.

  2009cited by this paper
• Mechanism of action of licensed vaccine adjuvants.

  2009cited by this paper
• Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

  2009cited by this paper
• A universal epitope-based influenza vaccine and its efficacy against H5N1.

  2009cited by this paper
• Recombinant Vesicular Stomatitis Virus Expressing Influenza Nucleoprotein Induces CD8 T-Cell Responses That Enhance Antibody-Mediated Protection after Lethal Challenge with Influenza Virus

  2009cited by this paper
• B Cells Promote Resistance to Heterosubtypic Strains of Influenza via Multiple Mechanisms1

  2008influential reference
• A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

  2008cited by this paper
• A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1

  2008influential reference
• Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

  2008cited by this paper
• Screening of Enzyme-Linked Immunospot Epitopes of Influenza A Virus Nucleocapsid Protein in BALB/c Mice and Studying on Their Relationship with Cytolytic T Lymphocytes Epitopes

  2008cited by this paper
• Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.

  2008cited by this paper
• Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

  2007cited by this paper
• Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1

  2007cited by this paper
• Rectification of Age-Associated Deficiency in Cytotoxic T Cell Response to Influenza A Virus by Immunization with Immune Complexes

  2007cited by this paper
• Heterosubtypic Immunity to Influenza A Virus Infection Requires a Properly Diversified Antibody Repertoire

  2007cited by this paper
• Making Better Influenza Virus

  2006cited by this paper
• Making Better Influenza Virus Vaccines?

  2006cited by this paper
• A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.

  2006cited by this paper
• Preparing for Pandemic Vaccination: An International Policy Agenda for Vaccine Development

  2005cited by this paper
• Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

  2005cited by this paper
• Helping the CD8+ T-cell response

  2004cited by this paper
• CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study

  2004cited by this paper
• Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens

  2003cited by this paper
• The annual production cycle for influenza vaccine.

  2003cited by this paper
• Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus.

  2002cited by this paper
• Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.

  2000cited by this paper
• Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.

  1999cited by this paper
• Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species.

  1999cited by this paper
• Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA

  1998cited by this paper
• Human Cytotoxic T-Lymphocyte Repertoire to Influenza A Viruses

  1998cited by this paper
• Role of the B‐cell response in recovery of mice from primary influenza virus infection

  1997cited by this paper
• Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.

  1996cited by this paper
• Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990

  1993cited by this paper
• Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses.

  1989cited by this paper
• Purified influenza virus nucleoprotein protects mice from lethal infection.

  1987cited by this paper
• Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes.

  1986cited by this paper
• Cytotoxic T-cell immunity to influenza.

  1983cited by this paper
• Expression of influenza A virus internal antigens on the surface of infected P815 cells.

  1981cited by this paper

• Expression and Purification of an NP-Hoc Fusion Protein: Utilizing Influenza A Nucleoprotein and Phage T4 Hoc Protein.

  2024cites this paper
• CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein

  2023influential citation
• Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants

  2022cites this paper
• Selecting and Using the Appropriate Influenza Vaccine for Each Individual

  2021cites this paper
• Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses

  2020influential citation
• Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats

  2019cites this paper
• jmbReview Optimized Expression , Purification , and Rapid Detection of Recombinant Influenza Nucleoproteins Expressed in Sf 9 Insect Cells

  2018cites this paper
• Protection by humoral elements independent of virus neutralization activity against an influenza virus challenge.

  2017cites this paper
• Strategies towards universal pandemic influenza vaccines

  2016influential citation
• Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice

  2015cites this paper
• Plant molecular farming for the production of industrial enzyme and vaccines

  2015cites this paper
• Augmentation de l'immunogénicité de la nucléoprotéine de l'influenza par multimérisation in vitro

  2015cites this paper
• Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice

  2015cites this paper